Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
CAMBRIDGE, Mass., March 18, 2016 -- Mersana Therapeutics, Inc. today announced that it will present two posters, one of which includes data on its new preclinical immunoconjugate, at the 2016 American Association for Cancer Research (AACR) Annual Meeting being held April 16-20, 2016, at the Ernest N. Morial Convention Center in New Orleans, LA.
Details of the posters being presented are as follows:
Title: Optimization of Lead Antibody Selection for XMT-1522, a Novel, Highly Potent HER2-Targeted Antibody-Drug Conjugate
Abstract Number: 596
Poster Session: Therapeutic Antibodies, Section 27
Date: Sunday, April 17, 2016
Time: 1:00 p.m. – 5:00 p.m. CT
Presenter: Natasha Bodyak, Ph.D., M.B.A., Executive Director, Biology, Mersana Therapeutics
The abstract describes the discovery and characterization of the novel anti-HER2 antibody used in XMT-1522, a novel HER2-targeting therapy based on Mersana’s Fleximer® immunoconjugate technology that is highly active in low HER2-expressing tumors and is fully combinable with current HER2 antibody therapeutics.
Title: Discovery and Preclinical Development of a Highly Potent NaPi2b-Targeted Antibody-Drug Conjugate with Significant Activity in Patient-Derived Non-Small Cell Lung Cancer (NSCLC) Xenograft Models
Abstract Number: 1194
Poster Session: Growth Factor Receptors and Surface Antigens as Therapeutic Targets, Section 15
Date: Monday, April 18, 2016
Time: 8:00 a.m. – 12:00 p.m. CT
Presenter: Natasha Bodyak, Ph.D., M.B.A., Executive Director, Biology, Mersana Therapeutics
XMT-1536, Mersana’s second preclinical candidate, is a highly potent anti-NaPi2b immunoconjugate comprised of an average of 15 auristatin molecules conjugated to XMT-1535, a novel humanized anti-NaPi2b antibody, via the Dolaflexin™ antibody-drug conjugate platform.
For more information about the AACR Annual Meeting, visit http://www.aacr.org/.
About Mersana Therapeutics
Mersana Therapeutics is advancing a proprietary pipeline of targeted oncology therapeutics leveraging its game-changing Fleximer® immunoconjugate technology. Mersana's first product candidate XMT-1522 has the potential to address significant unmet needs and improve patient outcomes in multiple oncology indications. Fleximer-based immunoconjugate molecules have been shown to have superior efficacy, including with targets previously considered not amenable to antibody-drug conjugate approaches. Mersana has collaborations utilizing Fleximer technology with Takeda, Merck KGaA, and Asana BioSciences. For more information, please visit www.mersana.com.
Media Contact 6 Degrees Tony Plohoros [email protected] (908) 591-2839 Investors Contact Stern Investor Relations, Inc. Jesse Baumgartner [email protected] (212) 362-1200
